Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile

Transcription

1 Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile

2 Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0) or reportstore@bioportfolio.com 2

3 Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile Summary Sanofi is a healthcare company, which focuses on the research, development, manufacture and marketing of therapeutic solutions. The company offers a wide range of medicines, vaccines and innovative therapeutic solutions. Its product portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and animal health products comprising anti-infectives, anti-parasitics, vaccines and other products. Sanofi also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women s health; and vitamins, minerals and supplements. It has operations across Europe, North America, Latin America, Asia-Pacific and Africa & Middle East. Sanofi is headquartered in Paris, France. Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Medical etrack deals database, and primary and secondary research. Scope - Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company's operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. 3

4 - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company s operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Additional Details Publisher : Global Data Reference : GDME3811D Number of Pages : 159 Report Format : PDF Publisher Information : 4

5 5

6 Table Of Contents for Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile Table of Contents Table of Contents 2List of Tables 5List of Figures 7Sanofi, Medical Equipment, Deals By Year, 2010 to YTD Sanofi, Medical Equipment Deals By Type, 2010 to YTD Sanofi, Medical Equipment, Deals By Region, 2010 to YTD Sanofi, Medical Equipment, Deals By Market, 2010 to YTD Sanofi, Medical Equipment, Deals Summary, 2010 to YTD Sanofi, Medical Equipment, Deal Details 15Asset Purchase 15Sanofi-Aventis Acquires Inhalation Assets From Siegfried 15Venture Financing 16Portal Instruments Raises USD25 Million in Series B Financing 16Portal Instruments Raises USD11 Million in Series A Venture Financing 17Partnerships 18Abiogen Pharma Enters Into Licensing Agreement With Genzyme 18CMIC Signs An Agreement With Genzyme 19Sanofi and Verily Life Sciences Form Joint Venture 20Google Life Sciences Enters into Agreement with Sanofi 21Veracyte Enters into Co-Promotion Agreement with Genzyme 22Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 23Genzyme Extends Co-Promotion Agreement with Veracyte 25Sanofi Enters into Co-Development Agreement with Medtronic 26Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 27HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 28Genzyme Enters Into Co-Marketing Agreement With Veracyte 29Foundation Medicine Enters Into Co- Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30Curetis Enters Into Agreement With Sanofi Pasteur For Unyvero Platform 31Institut Pasteur Korea Enters Into Co-Development Agreement With Sanofi-Aventis Korea 32Voluntis and CERITD Enters Into Co-Development Agreement With Sanofi 33Sanofi-Aventis Enters Into Distribution Agreement With Spineart 34AgaMatrix Signs Agreement With Sanofi-Aventis 35Merger 36Sanofi Japan and Genzyme Japan Merge 36Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 37Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 38F. Hoffmann-La Roche Enters Into Licensing Agreement With Genzyme 39Equity Offering 40Alnylam Pharma to Raise USD61.5 Million in Private Placement of Shares 40Debt Offering 42Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 42Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 43Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 44Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 45Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 46Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 47Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 48Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 50Sanofi Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 51Genzyme Completes Private Placement Of 5% Notes For US$500 Million 53Genzyme Completes Private Placement Of 3.6% Notes For US$500 Million 54Asset Transactions 55Nichi-iko Pharma To Acquire Business From Sanofi-Aventis 55Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 56Acquisition 58Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 58L'Oreal Plans To Sell Its Stake In Sanofi 59Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 60Sanofi Completes Acquisition Of Pluromed 62Sanofi-Aventis Completes Acquisition Of Genzyme 63Lab Corporation of America Completes Acquisition Of Genzyme Genetics From Genzyme 66Sanofi - Key Competitors 68Key Employees 69Locations And Subsidiaries 71Head Office 71Other Locations & Subsidiaries 71Recent Developments 88Strategy And Business Planning 88Jul 05, 2016: Sanofi Enters Into Confidentiality Agreement With Medivation And Will Be Provided Due Diligence Access And Confidential Information 88Apr 19, 2016: Sanofi Invests 300 Million To Expand Biologics Site in Belgium 89Aug 31, 2015: Sanofi To Collaborate With Google Life Sciences To Improve Diabetes Health Outcomes 90Jul 15, 2015: Sanofi Announces New, Global Business Unit Structure To Drive Future Growth 91Financial Announcements 92Oct 28, 2016: Sanofi Announces Strong Q Results 92Jul 29, 2016: Sanofi Announces Q Results 99Jul 29, 2016: Royalty report for Q and update on lixisenatide (Lyxumia/Adlyxin) and iglarlixi 107Apr 29, 2016: Solid Performance in the First Quarter of 2016 with Business EPS up 5.3% at Constant Exchange Rates 108Feb 09, 2016: Sanofi Delivered 2015 Business EPS Up 8.5% On A Reported Basis And Stable At Constant Exchange Rates Consistent With Guidance 114Jul 30, 2015: Sanofi delivers solid sales and business EPS(1) growth in Q Apr 30, 2015: Sanofi Delivers Q Business Eps Growth Of 2.6% At Cer And 12.8% On A Reported Basis 129Feb 05, 2015: Sanofi delivers Business EPS growth of 7.3% at CER in Corporate Communications 138Sep 30, 2016: Sanofi Appoints Alan Main to Executive Committee and Executive Vice President, Consumer Healthcare 138Sep 07, 2016: Sanofi Appoints New Research Head for Immunology and Inflammation 139Sep 06, 2016: 6

7 Sanofi Board Of Directors Provides Update 140May 23, 2016: Sanofi Announces Changes to Executive Committee Aligned to its Strategic Roadmap Mar 29, 2016: Sanofi Appoints Dr. Yong-Jun Liu as Head of Research 142Mar 10, 2016: Sanofi Appoints Dr. Ameet Nathwani to Executive Committee and Executive Vice President, Group Chief Medical Officer 143Nov 18, 2015: Xavier Darcos appointed President of the Sanofi Espoir Foundation 144May 26, 2015: Sanofi Appoints Suresh Kumar To The Executive Committee And Executive Vice President, External Affairs 145May 15, 2015: Sanofi Announces Departure Of Chief Strategy Officer 146Mar 06, 2015: Sanofi Appoints Robert Castaigne As Audit Committee Chairman 147Feb 19, 2015: Sanofi Appoints Olivier Brandicourt As Chief Executive Officer 148Feb 11, 2015: Sanofi To Layoff 100 Employees In Massachusetts 149Government and Public Interest 150Jun 13, 2016: Sanofi Files Definitive Consent Solicitation To Remove And Replace Medivation s Board 150Jun 01, 2016: Sanofi Requests Record Date for Consent Solicitation to Remove and Replace Medivation s Board of Directors 151Product News 152Aug 19, 2015: Paxman Cold Cap Chemotherapy Hair Loss Prevention Investigational Device - Clinical Trials Expand to Second Dallas Oncology Center 152Other Significant Developments 153May 25, 2016: Sanofi Files Consent Solicitation To Remove and Replace Medivation s Board 153Apr 19, 2016: Sanofi Invests 300 Million To Expand Biologics Site in Belgium 156Apr 19, 2016: Sanofi Invests 300 Million in its Biologics Site in Belgium to Develop its Monoclonal Antibodies Portfolio 157Sep 16, 2015: Sanofi's CSR Achievements Recognized In The Dow Jones Sustainability Indices 158Appendix 159Methodology 159About GlobalData 159Contact Us 159Disclaimer 159 7

8 List Of Tables in Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile List of Tables Sanofi, Medical Equipment, Key Facts, Sanofi, Medical Equipment, Deals Summary, 2010 to YTD Sanofi, Medical Equipment, Deals By Year, 2010 to YTD Sanofi, Medical Equipment Deals By Type, 2010 to YTD Sanofi, Medical Equipment, Deals By Region, 2010 to YTD Sanofi, Deals By Market, 2010 to YTD Sanofi, Medical Equipment, Deals Summary, 2010 to YTD Sanofi-Aventis Acquires Inhalation Assets From Siegfried 15 Portal Instruments Raises USD25 Million in Series B Financing 16 Portal Instruments Raises USD11 Million in Series A Venture Financing 17 Abiogen Pharma Enters Into Licensing Agreement With Genzyme 18 CMIC Signs An Agreement With Genzyme 19 Sanofi and Verily Life Sciences Form Joint Venture 20 Google Life Sciences Enters into Agreement with Sanofi 21 Veracyte Enters into Co-Promotion Agreement with Genzyme 22 Illumina Partners with AstraZeneca, Janssen and Sanofi to Develop NGS-Based Oncology Test System 23 Genzyme Extends Co-Promotion Agreement with Veracyte 25 Sanofi Enters into Co-Development Agreement with Medtronic 26 Institut Curie Enters Into Research Agreement With Sanofi To Develop Ovarian Cancer Treatments 27 HTG Molecular Diagnostics Enters Into Co-Development Agreement With sanofi-aventis 28 Genzyme Enters Into Co-Marketing Agreement With Veracyte 29 Foundation Medicine Enters Into Co-Development Agreement With Sanofi For Genetic Biomarkers And Potential Diagnostics 30 Curetis Enters Into Agreement With Sanofi Pasteur For Unyvero Platform 31 Institut Pasteur Korea Enters Into Co-Development Agreement With Sanofi-Aventis Korea 32 Voluntis and CERITD Enters Into Co-Development Agreement With Sanofi 33 Sanofi-Aventis Enters Into Distribution Agreement With Spineart 34 AgaMatrix Signs Agreement With Sanofi-Aventis 35 8

9 Sanofi Japan and Genzyme Japan Merge 36 Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Duplex Gene Therapy Vector Technology 37 Asklepios BioPharma Enters Into Licensing Agreement With Genzyme For Intra-Strand Base-Pairing Technology 38 F. Hoffmann-La Roche Enters Into Licensing Agreement With Genzyme 39 Alnylam Pharma to Raise USD61.5 Million in Private Placement of Shares 40 Sanofi Prices Public Offering of 1.5% Notes Due 2025 for USD850 Million 42 Sanofi Prices Public Offering of Notes Due 2019 for USD850 Million 43 Sanofi Prices Public Offering of 1.75% Notes Due 2026 for USD1.64 Billion 44 Sanofi Prices Public Offering of 1.125% Notes Due 2022 for USD1.31 Billion 45 Sanofi Prices Public Offering Of Bonds Due 2023 For US$1.35 Billion 46 Sanofi Prices Public Offering Of Bonds Due 2020 For US$1.3 Billion 47 Sanofi Completes Public Offering Of Notes Due 2018 For US$1.5 Billion 48 Sanofi Completes Public Offering Of Notes Due 2017 For US$960 Million 50 Sanofi Completes Public Offering Of Senior Unsecured Notes Due 2014 For US$1,000 Million 51 Genzyme Completes Private Placement Of 5% Notes For US$500 Million 53 Genzyme Completes Private Placement Of 3.6% Notes For US$500 Million 54 Nichi-iko Pharma To Acquire Business From Sanofi-Aventis 55 Genzyme Completes Sale Of Its Diagnostic Business To Sekisui Chemical 56 Sanofi-Aventis To Acquire Minority Stake In Shantha Biotechnics For US$123 Million 58 L'Oreal Plans To Sell Its Stake In Sanofi 59 Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 60 Sanofi Completes Acquisition Of Pluromed 62 Sanofi-Aventis Completes Acquisition Of Genzyme 63 Lab Corporation of America Completes Acquisition Of Genzyme Genetics From Genzyme 66 Sanofi, Key Competitors 68 Sanofi, Key Employees 69 Sanofi, Subsidiaries 71 9

10 List Of Figures, Charts and Diagrams in Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile List of Figures Sanofi, Medical Equipment, Deals by Type, 2010 to YTD Sanofi, Medical Equipment, Deals By Year, 2010 to YTD Sanofi, Medical Equipment, Deals By Region, 2010 to YTD Sanofi, Medical Equipment, Deals By Market, 2010 to YTD Sanofi, Medical Equipment, Deals By Year, 2010 to YTD Sanofi, Medical Equipment, Deals by Type, 2010 to YTD Sanofi, Medical Equipment, Deals By Region, 2010 to YTD Sanofi, Medical Equipment, Deals by Market, 2010 to YTD

11 How to Buy... Sanofi (SAN) - Medical Equipment - Deals and Alliances Profile Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0) We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $250 Single User Price $500 Site License Price $750 Enterprise License Price Payment Options: (please tick one) Online Credit Card (we will you the invoice with a payment link) Direct Wire Transfer (we will you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0) We will be delighted to give you our personal attention. 11